Cost Effectiveness Analysis Of Evolocumab, A PCSK9 Inhibitor, From The US Societal Perspective
May 1, 2018, 00:00 AM
10.1016/j.jval.2018.04.368
https://www.valueinhealthjournal.com/article/S1098-3015(18)30668-5/fulltext
Section Title :
Section Order :
1221
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)30668-5&doi=10.1016/j.jval.2018.04.368